Academic staff

HomeAcademic staffDr Ruth Gyereh
Dr Ruth Gyereh

Dr Ruth Gyereh

Human Sciences

  • 0
    total views of outputs
  • 0
    total downloads of outputs
  • 0
    views of outputs this month
  • 0
    downloads of outputs this month

I am a Lecturer in Biomedical Science at the School of Applied Science. I joined LSBU in 2023 after successfully completing my doctorate at Middlesex University, London. Before my tenure at LSBU, I served as a registered Biomedical Scientist at the Doctors Laboratory in London and gained international experience at Ho Teaching Hospital in Ghana.

Currently, I co-lead and lecture in Haematology and Blood Transfusion, and the module leader for Cancer Biology and Therapy. In addition, I contribute to the education of our students by teaching Anatomy & Physiology and serving as a project supervisor for Level 6 students.

Drawing upon my diverse background and extensive experiences in both research and clinical settings, my expertise lies in blood cancer/leukaemia, focusing on the field of anti-cancer peptides. I focus particularly on bioactive peptides, with a specialised emphasis on their role as anti-leukemic agents.

My recent project: Investigating the anti-leukemic effect of a novel bioactive peptide, QUB-2392 and the underlying mechanisms of action.

My preliminary research findings on QUB-2392 involving four distinct leukaemia cell lines (in vitro studies) using various molecular techniques, including mass spectrometry-based proteomics and gene profiling, indicate significant anti-leukemic activity. The primary mechanism of action (MOA) underlying QUB-2392 against the investigated leukaemia cells involves apoptosis induction, complemented by its anti-proliferative, immune-modulatory, DNA repair, and onco-suppressive properties. These results underscore the therapeutic potential of QUB-2392 for targeting leukaemia.

Furthermore, the use of combination therapy involving a conventional anti-cancer agent, doxorubicin, at remarkably low concentrations, demonstrates a synergistic efficacy in the investigated leukaemia cells.

The current research serves as a pioneering foundation, opening avenues for exploring other research gaps. Given that all experiments were conducted through in vitro studies, the translational potential of QUB-2392 in clinical settings remains to be explored via in vivo studies. It is imperative to assess the peptide's efficacy, safety, and pharmacokinetics in animal models, paving the way for eventual clinical trials.

During my PhD studies at Middlesex University, London, I actively shared my research findings through presentations at various conferences and seminars. A notable recent instance includes my role as a guest speaker at the Centre for Investigative and Diagnostic Oncology, School of Science and Technology, Natural Science Department, Middlesex University, London. On January 11th, 2024, I presented a virtual seminar on the topic: "Anti-leukaemic activity of a novel bioactive peptide, QUB-2392, against human leukaemia cell lines by proteomics and gene profiling."

Furthermore, in presenting my research, I was honoured with the Best Oral Presentation award at the Research Students' Summer Conference (RSSC) in 2021. The focus of my presentation was on ‘’investigating the anti-leukemic effect of Antimicrobial Peptides and the underlying mechanisms’’ at the Natural Science Department, Middlesex University, London.

Courses taught

Biomedical Sciences - BSc (Hons)

PhD (Biomedical Science)

Middlesex University, London

MSc Haematology & Blood Transfusion Science

Middlesex University, London.

BSc Medical Laboratory Science

University of Cape Cost, Ghana.

Diploma Medical Laboratory Science

College of Health, Ghana.